Study of Motilitone to Treat Functional Dyspepsia

Phase 2

Completed

• Conditions: Dyspepsia
• Interventions: Drug: Motilitone 30mg; Drug: Placebo

• Registration Number: NCT02365701
• Lead Sponsor: Dong-A ST Co., Ltd.

Brief Summary

This study is to evaluate efficacy of the investigational drug Motilitone at 90 mg in patients with Functional Dyspepsia as measured by change in maximum tolerated volume and aggregate symptom score on the nutrient drink test.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-09-05
• Study First Submitted QC: 2015-02-11
• Study First Posted: 2015-02-19
• Study Start: 2015-06
• Primary Completion: 2018-02
• Study Completion: 2018-02
• Status Verified: 2018-06
• Last Update Submitted: 2019-05-20
• Last Update Posted: 2019-05-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• (1) Subject fulfilling Rome III criteria for Functional Dyspepsia: They must have one or more of the following:

  1. Bothersome postprandial fullness
  2. Early satiation
  3. Epigastric pain
  4. Epigastric burning AND No evidence of structural disease at upper endoscopy within last 3 months that is likely to explain the symptoms These must be fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.

• (2) At least a moderate or severe level within the previous 3 months for two of the following eight symptoms: upper abdominal pain, upper abdominal discomfort, postprandial fullness, upper abdominal bloating, early satiation, nausea, vomiting or excessive belching (each symptom rated as 0: None, 1: Mild, 2: Moderate, 3: Severe).

• (3) Subjects should be able to provide a written informed consent.

Exclusion Criteria

• (1) Subject currently on medication for another study or who participated in another clinical trial or study within 4 weeks before the start of this study.
• (2) Women of childbearing potential who are not using contraception and pregnant or lactating women.
• (3) Subject who had surgery that may affect gastrointestinal motility.
• (4) Subject with known history of gastric bleeding, intestinal obstruction or perforation.
• (5) Subject with known history of celiac disease, inflammatory bowel disease (Crohn's disease, ulcerative colitis) or microscopic colitis.
• (6) Subject who had any of the diseases such as reflux esophagitis, gastroduodenal ulcer, gastric adenocarcinoma, esophageal adenocarcinoma, pancreatic disease, etc. that may be an organic cause of dyspepsia.
• (7) Subject with liver dysfunction (serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase is at least 2.5 times higher than ULN).
• (8) Subject with renal dysfunction (Serum creatinine level is at least 1.5 times higher than ULN).
• (9) Subject with a serious cardiovascular (including known baseline QT prolongation defined by >450 msec) or respiratory illness.
• (10) Subject with diagnosed psychotic illnesses, substance dependence or alcoholism.
• (11) Subject currently taking drugs that may affect gastrointestinal motility (e.g., anticholinergic, Reglan, erythromycin, azithromycin, Domperidone, etc.), Buspirone, Acotiamide, Tramadol, nonsteroidal anti-inflammatory drug, systemic corticosteroids, and antidepressants, etc. within last 2 weeks of randomization.
• (12) Medications that can affect QT within last 2 weeks of randomization.
• (13) Subjects on herbal supplements for Functional Dyspepsia within last 2 weeks of randomization.
• (14) Subjects with gastric electric stimulator in place.
• (15) Subjects on narcotics or benzodiazepines within 7 days of randomization.
• (16) Subjects with score > 12 for anxiety or depression on the Hospital Anxiety and Depression Scale (HADS).
• (17) Vulnerable study population

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Motilitone 30mg	Motilitone 30mg	Motilitone will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 4 weeks.
Placebo	Placebo	Placebo (same formulation as Motilitone but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 4 weeks.

Primary Outcome Measures

Name	Time	Method
Change in maximum tolerated volume by nutrient drink test	week -2, week 4
Change in aggregate symptom score by nutrient drink test	week -2, week 4

Trial Locations

Locations (1)

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States